<DOC>
	<DOCNO>NCT01031420</DOCNO>
	<brief_summary>Standard treatment early stage bladder cancer chemotherapy methotrexate ( M ) , vinblastine ( V ) , adriamycin ( A ) , cisplatin ( C ) follow surgical removal remain cancer bladder intent cure . The MV chemotherapy usually give every 14 day AC give along 28 day . This study look give drug dos closer together , drug every 14 day , support growth factor medication promote growth white blood cell platelet allow chemotherapy finish sooner surgery do sooner .</brief_summary>
	<brief_title>Dose Dense MVAC Muscle Invasive Bladder Cancer</brief_title>
	<detailed_description>Primary Objective To assess rate complete response ( pT0 ) cystectomy ureterectomy follow preoperative dose dense MVAC ( DD-MVAC ) patient muscle invasive urothelial carcinoma bladder high grade upper tract urothelial carcinoma . Secondary Objectives To assess toxicity profile DD-MVAC give neoadjuvant setting : To define number patient complete three cycle treatment without dose reduction , compare incidence toxicity historical standard describe Grossman et al . To assess 5 year overall relapse free survival patient receive neoadjuvant DD-MVAC . To compare complete response rate follow subgroup study patient : Among bladder patient : Clinical N0 versus N1 ( Appendix B ) Among bladder patient : T2 stage without high risk feature versus T2 high risk feature plus &gt; T2 stage . Three 14 day cycle : Methotrexate 30 mg/m2 IV push infusion 2-3 minute . Day 1 Vinblastine 3 mg/m2 Slow IV push infusion Day 1 Doxorubicin 30 mg/m2 Slow IV push infusion 15 minute Day 1 Cisplatin 70 mg/m2 IV infusion 4 hour Note : May divide dose two sequential day ( 35 mg/m2/d x 2 day ) creatinine clearance 50-59 mL/min Day 1* ( divide Day 1 Day 2 ) Pegfilgrastim 6 mg SQ 24-48 hour completion chemotherapy . Followed 4-8 week radical cystectomy/ureterectomy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>histologically confirm urothelial carcinoma bladder , ureter , renal pelvis . T2T4 muscle invasion must establish TURBT . Upper tract must high grade . N0N1 eligible . candidate radical cystectomy , nephroureterectomy , segmental ureterectomy goal cure . &gt; /= 18 year old ECOG performance status 01 . Adequate marrow organ function . May enter therapeutic anticoagulation safely hold perioperative period . No woman childbearing potential , pregnant breastfeeding . LVEF &gt; /= 50 % Patients history nonurothelial malignancy may enroll : 1 ) evidence distant disease w/in last year . 2 ) No anticancer treatment &gt; /= 1 year adjuvant treatment treatment secondary prevention . 3 ) Less 360 mg/m2 lifetime dose adriamycin . ability understand willingness sign write informed consent HIPAA . Intravesicular therapy w/in 4 week study entry recover adverse effect agent administer 4 week earlier . Patients may receive investigational agent within 4 week study entry . History allergic reaction attribute compound similar chemical biologic composition Methotrexate , Vinblastine , Adriamycin Cisplatin agent use study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study due potential teratogenic abortifacient effect cytotoxic chemotherapy . Known HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction cytotoxic chemotherapy . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . . Patients undergone prior pelvic radiation exclude due risk life threaten myelosuppression . Patients receive previous systemic chemotherapy radiation therapy urothelial carcinoma cytotoxic chemotherapy another malignancy within 1 year study entry ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>bladder</keyword>
	<keyword>cancer</keyword>
	<keyword>invasive</keyword>
</DOC>